Addressing Misunderstandings in Applying HBV Treatment Guidelines

Download All
In this series of concise MedicalMinute presentations and accompanying downloadable slides, expert faculty interpet key guideline recommendations to address common misunderstandings in the management of patients with HBV infection.
Anna Christina L. dela Cruz, MD
Robert G. Gish, MD
Paul Y. Kwo, MD
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD

AASLD Guidelines

Determining the level of fibrosis is key in evaluating patients for HBV treatment candidacy. How, when, and why should we incorporate fibrosis assessments into clinical practice? Here’s my take.

Paul Y. Kwo, MD Released: February 18, 2021

How I incorporate family history into HBV treatment and monitoring decisions in certain clinical gray zones.

Anna Christina L. dela Cruz, MD Released: April 15, 2021

This concise MedicalMinute presentation reviews the natural history of HBV infection and interpreting serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.

Paul Y. Kwo, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: February 16, 2021 Expired: February 15, 2022

This concise MedicalMinute presentation reviews the AASLD guidelines on monitoring and treatment for patients with HBV infection, including a brief discussion of HCC risk in various patient populations.

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 26, 2021 Expired: March 25, 2022

This concise MedicalMinute presentation reviews the AASLD recommendations on methods to assess liver fibrosis and inflammation and data and guidance on translating test results into management decisions.

Anna Christina L. dela Cruz, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 20, 2021 Expired: April 19, 2022

In episode 2 of this ongoing series, listen to a conversation between Robert G. Gish, MD, FAASLD, and patient and advocate, Alan Wang, on approaches to destigmatize HBV infection and remove barriers to care.

Robert G. Gish, MD Released: April 12, 2021

Review AASLD guideline recommendations informing HBV pretreatment evaluation, including serology, HBV DNA, and fibrosis assessments to determine treatment candidacy.

Paul Y. Kwo, MD Released: February 16, 2021

Review key data and AASLD guideline recommendations on HCC risk, considerations for treatment, and optimal HCC monitoring.

Mindie H. Nguyen, MD, MAS, AGAF, FAASLD Released: March 26, 2021

Review key data and AASLD guideline recommendations on methods to evaluate liver fibrosis and inflammation to guide management decisions for patients with HBV infection.

Anna Christina L. dela Cruz, MD Released: April 20, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue